January 1, 1995Current Opinion in Hematology
Thrombopoietin and its receptor, the proto-oncogene c-mpl
Key result
Thrombopoietin potently stimulates platelet production via the c-mpl receptor to potentially treat thrombocytopenia.
Why the study?
The identification and characterization of thrombopoietin and its receptor c-mpl are fundamental to understanding platelet production regulation and related disorders.
Design
Review article
Authors
Discussion
Loading...
Member takes
Implication
May enable targeted therapies for thrombocytopenia; leaves open clinical translation pending trials.
PICO
P
Population
Thrombocytopenia
I
Intervention / Comparator
Thrombopoietin
The discovery and cloning of thrombopoietin opens new therapeutic avenues for managing thrombocytopenia and potentially enabling the mass production of functional platelets for transfusion.
Cite This Study
William Vainchenker (1995) conducted a review in Thrombocytopenia. Thrombopoietin was evaluated. Thrombopoietin, the newly identified ligand for the c-mpl receptor, is a potent stimulator of platelet production with potential applications for managing thrombocytopenia.